C.M.L. Hermans - Wageningen University & Research

基本信息

浏览量：0

职业迁徙

个人简介

C.M.L. Hermans currently works at the Wageningen Environmental Research, Wageningen University & Research. C.M.L. does research in Animal Science and Environmental Science. Her current project is Plant Benefits for health and wellbeing.

研究兴趣

论文共 658 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Moving Towards Normalization of Haemostasis and Health Equity: Evolving Treatment Goals for Haemophilia A

Pal Andre Holme,Jan Blatny,Pratima Chowdary,Riitta Lassila,Niamh O'Connell,Cedric Hermans,Maria Teresa Alvarez Roman,Claude Negrier,Antonio Coppola,Johannes Oldenburg

Haemophiliano. 5 (2024): 1109-1114

引用0浏览0WOS引用

Characterisation of the First Global VWD Cohort from the WFH World Bleeding Disorders Registry

Emily Ayoub,Donna Coffin, Pamela Dakik,Ellia Tootoonchian,Barbara Konkle, Ticiana Carvalho-Pereira,Nathan Connell,Jameela Sathar,Saliou Diop,Cedric Hermans,Catherine Lambert,Jamie O'Hara,Glenn F. Pierce,Emna Gouider,Alfonso Iorio

HAEMOPHILIA (2024): 195-196

引用0浏览0引用

Challenges in determining the severity of haemophilia A: An insight in discrepancies between factor VIII assays

M. -A. van Dievoet, I. Derclaye, S. Desmet, C. Gavard,C. Lambert,C. Hermans

HAEMOPHILIA (2024): 37-37

引用0浏览0引用

Levels, Determinants and Predictive Value of D-Dimer in Patients on Long-Term Direct Oral Anticoagulant for Venous Thrombo-Embolic Disease

Thibault Masse,Catherine Lambert,Andrea Penaloza,Cedric Hermans

Bloodno. Supplement 1 (2024): 2636-2636

引用0浏览0引用

Change in Hemophilia Joint Health Score (HJHS) During the Phase 3 XTEND-1 Study of Efanesoctocog Alfa in Patients with Severe Hemophilia A

R. Klamroth,A. von Drygalski,C. Hermans,E. Santagostino, J. Dumont,L. Abad-Franch,A. Willemze,L. Khoo

Hämostaseologie (2024)

引用0浏览0引用

Proactive Systematic Hemophilia Carrier Screening: A Step Towards Gender Equity in Hemophilia Care

Evelien Krumb,Catherine Lambert,An Van Damme,Cedric Hermans

BLOOD ADVANCESno. 20 (2024): 5268-5278

引用0浏览0WOS引用

Response to Gene Therapy in Haemophilia B: Ranges of Factor IX Sustained after 3 Years in HOPE-B Etranacogene Dezaparvovec Gene Therapy Trial

Cedric Hermans,Michiel Coppens,Sandra Le Quellec,Nicholas Galante,Douglass Drelich,Steven Pipe

HAEMOPHILIA (2024): 25-25

引用0浏览0引用

HIV Comorbid Infection and Etranacogene Dezaparvovec Therapy: Efficacy and Safety Results from Phase 2b and Pivotal Phase 3 HOPE-B Trials 3 Years after Administration

S. Pipe,E. Gomez,C. Hermans,A. Giermasz,P. Kampmann,R. Lemons,N. Galante,S. Le Quellec,P. Monahan

Hämostaseologie (2024)

引用0浏览0引用

International Data Integration Program of the WFH World Bleeding Disorders Registry: Bringing Europe Data to the Global Stage

E. Ayoub,D. Coffin, C. Lambert,B. Konkle,C. Hermans,J. O'Hara,S. Diop,G. F. Pierce,E. Gouider,A. Iorio

HAEMOPHILIA (2024): 56-57

引用0浏览0引用

Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany

Niklaus Meier,Hendrik Fuchs,Katya Galactionova,Cédric Hermans,Mark Pletscher,Matthias Schwenkglenks

PharmacoEconomics - open (2024)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn